To assist physicians in their use of vasoactive drugs, professional associations have proposed guidelines that allow an opportunity to administer epinephrine or a combination of norepinephrine and dobutamine to more severely ill patients [4] . A recently reported study [59] indicated that these two strategies were equivalent in terms of both efficacy and safety. Interest in vasopressin is reflected in a growing number of publications, but the available evidence does not allow its integration into a global therapeutic scheme. However, recent data [60] may justify reconsideration of vasopressin in severe sepsis management guidelines in the near future. The VAsopressin in Septic Shock Trial (VASST) study [61] is currently comparing vasopressin with norepinephrine as initial vasopressor in septic shock patients. Because the study is not yet completed, no analysis or definite conclusions can yet be drawn from this trial.